Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115003 | 0.84 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL396999 | 0.81 | TSHR (0.39) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Methane SCHEMBL27945359 | 0.79 | TSHR (0.37) | LMNAL3MBTL1PDE4ATDP1 | |
| SCHEMBL3371759 | 0.76 | PTPN1 (0.36) | — | |
| SCHEMBL14555987 | 0.75 | LMNA (0.42) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Cadaverine Tartrate SCHEMBL27695422 | 0.73 | PDE4A (0.44) | LMNAPDE4AUSP2SLCO1B1OR51E2 | |
| SCHEMBL7490863 | 0.73 | USP2 (0.41) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL10441292 | 0.73 | USP2 (0.41) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| E968 SCHEMBL1603745 | 0.72 | LMNA (0.47) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL18451403 | 0.72 | LMNA (0.44) | LMNAL3MBTL1PDE4ATDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117925839-B | Biomarker for evaluating recurrence risk after treatment of multiple myeloma and application thereof | 南通大学附属医院 | 2025-04-01 | — | — | CN | disclosed |
| CN-117925839-A | Biomarker for evaluating recurrence risk after treatment of multiple myeloma and application thereof | 南通大学附属医院 | 2024-04-26 | — | — | CN | disclosed |
| EP-0734386-B1 | PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES | ABBOTT LAB (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-0821685-B1 | INDOLE-3-CARBONYL AND INDOLE-3-SULFONYL DERIVATIVES AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LAB (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-0595924-B1 | PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LAB (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0821685-A1 | INDOLE-3-CARBONYL AND INDOLE-3-SULFONYL DERIVATIVES AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1998-02-04 | — | — | EP | disclosed |
| US-5654305-A | TREATING PLATELET ACTIVATING FACTOR MEDIATED DISORDERS | ABBOTT LABORATORIES (US) | 1997-08-05 | — | — | US | disclosed |
| US-5643922-A | Indole cyclohexyl platelet activating factor antagonists | ABBOTT LABORATORIES (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1996033196-A1 | INDOLE-3-CARBONYL AND INDOLE-3-SULFONYL DERIVATIVES AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-10-24 | — | — | WO | disclosed |
| US-5567711-A | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists | ABBOTT LABORATORIES (US) | 1996-10-22 | — | — | US | disclosed |
| WO-1992014732-A1 | INDOLES USEFUL AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1992-09-03 | — | — | WO | disclosed |
| US-5144035-A | Chemical intermediates for platelet activating factor antagonists | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-09-01 | — | — | US | disclosed |
| EP-0499987-A1 | Platelet activating factor antagonists | ABBOTT LABORATORIES (US) | 1992-08-26 | — | — | EP | disclosed |
| US-5120751-A | Platelet activating factor antagonist | ABBOTT LABORATORIES (US) | 1992-06-09 | — | — | US | disclosed |
| US-5120749-A | Treatment of anaphylactic shock, respiratory distress syndrome, acute inflammation, delayed cellulosr immunity, parturtition, fetal lung maturation, and cellular differentiation | ABBOTT LABORATORIES (US) | 1992-06-09 | — | — | US | disclosed |
| EP-0425134-A1 | Condensed pyrrolo derivatives, process for their preparation and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| US-4948795-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1990-08-14 | — | — | US | disclosed |
| EP-0350145-A2 | Pyridylthiazolidine carboxamide derivatives and their intermediates and production of both | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-01-10 | — | — | EP | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |